RoosterBio Expands Frederick, Maryland, Operations Campus
12/19/2019
The addition of 5,000 square feet to its existing 15,500 footprint supports the company’s expansion efforts and provides infrastructure to meet a growing international demand for its standardized hMSC bioprocess tools. The company is a leading supplier of human mesenchymal stem/stromal cell working cell banks and hMSC bioprocess systems.
RoosterBio reported its headquarters at The Offices at Westview serves as a center of excellence, incorporating the latest scale up bioprocessing technology and allows the company to quality test its cells and media in a variety of conditions and applications. The new space will increase shipping capabilities for a growing international network by the end of the year.
RoosterBio announced the first expansion of its facility earlier this year which served as a catalyst for its strategic international growth initiatives. The company plans to launch an international presence in Asia during the first half of 2020.
According to company officials, by strengthening its cell manufacturing solution portfolio and presence in the Asia Pacific and Europe, RoosterBio is giving more people around the world the ability to advance regenerative medicine cures.
“Our team has been working diligently this year to grow our customer base across the globe, now shipping to 26 countries and the need to expand our facility is a result of the industry validating our value proposition,” said RoosterBio’s CEO Margot Connor. “As our efforts have increased, we’ve increased our employee base by nearly 30% this year and we’re excited about our continued annual growth rate.” Connor added, “We’re taking RoosterBio to the next level in the international hMSC marketplace.”
Company officials explained, these enhancements build on RoosterBio’s proven track record of industrializing the supply chain for the new field of regenerative medicine. The products that RoosterBio has commercialized are designed to standardize hMSC manufacturing with consistent cGMP product offerings, removing years of time, and millions of dollars, from traditional mesenchymal cell therapeutic product development and clinical translation efforts. RoosterBio said it will also be launching a cGMP version of its extracellular vesicle production tools in early 2020.
Project Announcements
GE Appliances Expands Jefferson County, Kentucky, Operations
06/30/2025
ValorFlex Packaging Plans Bowling Green, Kentucky, Production Operations
06/30/2025
Neuro.io Plans Terrebonne Parish, Louisiana, Operations
06/30/2025
Germany-Based MTU Maintenance Expands Fort Worth, Texas, MRO Operations
06/30/2025
Cascade Die Casting Group Expands High Point, North Carolina, Manufacturing Operations
06/30/2025
BuildOps Plans Raleigh, North Carolina, Operations
06/30/2025
Most Read
-
20th Annual Area Development Gold and Silver Shovel Awards
Q2 2025
-
First Person: Joe Capes, CEO, LiquidStack
Q2 2025
-
The Legal Limits of DEI in Incentives Agreements, Hiring, and Contracting
Q2 2025
-
From Silicon to Server: Mapping the Data Center Supply Chain
Q2 2025
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
Rethinking Life Sciences Site Selection in a Resilient and Dynamic Market
Q2 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024